Skip to main content
. 2021 Nov 24;13(23):5896. doi: 10.3390/cancers13235896

Table 3.

First-line treatment options in metastatic CCRC.

Standard of Care Alternative in Patients Who Cannot Receive Immunotherapy
IMDC favourable risk Nivolumab/cabozantinib
Pembrolizumab/axitinib
Pembrolizumab/lenvatinib
Sunitinib
Pazopanib
IMDC intermediate and poor risk Nivolumab/cabozantinib
Pembrolizumab/axitinib
Pembrolizumab/lenvatinib
Nivolumab/ipilimumab
Cabozantinib
Sunitinb
pazopanib